BackEucrates Biomedical Acquisition Overview

Eucrates Biomedical Acquisition Total Liabilities

Eucrates Biomedical Acquisition's total liabilities is $3.9M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$3.95M
↓ 31.90% YoYΔ $-1.85M vs prior year quarter

Peer average

Loading

Eucrates Biomedical Acquisition Total Liabilities History

Loading

Eucrates Biomedical Acquisition vs. peers: Total Liabilities Comparison

Loading

Eucrates Biomedical Acquisition Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Eucrates Biomedical Acquisition (EUCR) FAQ

Eucrates Biomedical Acquisition posts a total liabilities of $3.9M as of December 2022. That compares with $5.8M in the prior-year period — down 31.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Eucrates Biomedical Acquisition's total liabilities was $5.8M. The latest reading is $3.9M — a 31.9% year-over-year decrease (period ending December 2022). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of Eucrates Biomedical Acquisition's financial statement story. At $3.9M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for EUCR's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Eucrates Biomedical Acquisition's other metric pages and overview cover the third.